The short version
24 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Emtricitabine and tenofovir disoproxil fumarate · EMTRICITABINE 133 mg/1; TENOFOVIR DISOPROXIL FUMARATE 200 mg/1 · Tablet, Film Coated · Oral · Zydus Lifesciences Limited
NDC 70771-1621-03 · 30 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
24 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 61958-0704-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Aurobindo Pharma Limited | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| NuCare Pharmaceuticals, Inc. | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Patheon Inc. | EMTRICITABINE 167 mg/1; TENOFOVIR DISOPROXIL FUMARATE 250 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Patheon Inc. | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Amneal Pharmaceuticals NY LLC | EMTRICITABINE 167 mg/1; TENOFOVIR DISOPROXIL FUMARATE 250 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | EMTRICITABINE 100 mg/1; TENOFOVIR DISOPROXIL FUMARATE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | EMTRICITABINE 133 mg/1; TENOFOVIR DISOPROXIL FUMARATE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | EMTRICITABINE 133 mg/1; TENOFOVIR DISOPROXIL FUMARATE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | EMTRICITABINE 167 mg/1; TENOFOVIR DISOPROXIL FUMARATE 250 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | EMTRICITABINE 100 mg/1; TENOFOVIR DISOPROXIL FUMARATE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| DirectRx | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Exelan Pharmaceuticals, Inc. | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Gilead Sciences, Inc | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Gilead Sciences, Inc | EMTRICITABINE 133 mg/1; TENOFOVIR DISOPROXIL FUMARATE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Gilead Sciences, Inc | EMTRICITABINE 100 mg/1; TENOFOVIR DISOPROXIL FUMARATE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Gilead Sciences, Inc | EMTRICITABINE 167 mg/1; TENOFOVIR DISOPROXIL FUMARATE 250 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Laurus Labs Limited | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NorthStar RxLLC | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals,Inc. | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Quallent Pharmaceuticals Health Llc | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Redpharm Drug | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rottendorf Pharma GmbH | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Takeda GmbH | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | EMTRICITABINE 100 mg/1; TENOFOVIR DISOPROXIL FUMARATE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | EMTRICITABINE 167 mg/1; TENOFOVIR DISOPROXIL FUMARATE 250 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | EMTRICITABINE 133 mg/1; TENOFOVIR DISOPROXIL FUMARATE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | EMTRICITABINE 167 mg/1; TENOFOVIR DISOPROXIL FUMARATE 250 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | EMTRICITABINE 133 mg/1; TENOFOVIR DISOPROXIL FUMARATE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | EMTRICITABINE 100 mg/1; TENOFOVIR DISOPROXIL FUMARATE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
| Cipla USA Inc. | EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Emtricitabine and tenofovir disoproxil fumarate — NDC 70771-1621-03," retrieved September 3, 2026, https://drugdashboards.com/drug/70771162103.
Free to cite with attribution — see how the data is put together.